• Users Online: 42992
  • Home
  • Print this page
  • Email this page
This article has been cited by
1
Katrin Engelmann,Klio Ai Becker
.2011;()143
[DOI]
2The pathogenesis of early retinal changes of diabetic retinopathy
G. B. Arden,S. Sivaprasad
Documenta Ophthalmologica.2012;124(1)15
[DOI]
3Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study
Raquel Costa,Ângela Carneiro,Ana Rocha,Ana Pirraco,Manuel Falcão,Luísa Vasques,Raquel Soares
Journal of Cellular Biochemistry.2009;108(6)1410
[DOI]
4A review of anti-VEGF agents for proliferative diabetic retinopathy
P Osaadon,X J Fagan,T Lifshitz,J Levy
Eye.2014;28(5)510
[DOI]
5Reducible Polyethylenimine Nanoparticles for Efficient siRNA Delivery in Corneal Neovascularization Therapy
Hyounkoo Han,Sohee Son,Sejin Son,Namho Kim,Ji Young Yhee,Jae Hyeop Lee,Jun-Sub Choi,Choun-Ki Joo,Hohyeon Lee,Duhwan Lee,Won Jong Kim,Sun Hwa Kim,Ick Chan Kwon,Hyuncheol Kim,Kwangmeyung Kim
Macromolecular Bioscience.2016;16(11)1583
[DOI]
6Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab
Alper Bilgic,Laurent Kodjikian,Jay Chhablani,Anand Sudhalkar,Megha Trivedi,Viraj Vasavada,Vaishali Vasavada,Shail Vasavada,Samaresh Srivastava,Deepak Bhojwani,Aditya Sudhalkar
Journal of Ophthalmology.2020;2020(11)1
[DOI]
7New VEGF antagonists as possible therapeutic agents in vascular disease
M Slevin,P Kumar,Quiyu Wang,S Kumar,J Gaffney,M Grau-Olivares,J Krupinski
Expert Opinion on Investigational Drugs.2008;17(9)1301
[DOI]
8Differences in Vitreous Protein Profiles in Patients With Proliferative Diabetic Retinopathy Before and After Ranibizumab Treatment
Xinping She,Chen Zou,Zhi Zheng
Frontiers in Medicine.2022;9(9)1301
[DOI]
9Microvascular complications and diabetic retinopathy: recent advances and future implications
Megha Barot,Mitan R Gokulgandhi,Sulabh Patel,Ashim K Mitra
Future Medicinal Chemistry.2013;5(3)301
[DOI]
10Review of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy
Maria Stephanie R. Jardeleza,Joan W. Miller
Seminars in Ophthalmology.2009;24(2)87
[DOI]
11COMPARISON OF VISUAL ACUITY OUTCOME IN PROLIFERATIVE DIABETIC RETINOPATHY(PDR) BETWEEN INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB INJECTIONS
Kalishankar Das,Shafaque Sahar,Kesha Shah,Athokpam Poireiton
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2022;24(2)35
[DOI]
12Treatment of proliferative diabetic retinopathy with anti-VEGF agents
Aysha Salam,Raeba Mathew,Sobha Sivaprasad
Acta Ophthalmologica.2011;89(5)405
[DOI]
13Current intravitreal therapy and ocular hypertension: A review
Aditya Sudhalkar,Alper Bilgic,Shail Vasavada,Laurent Kodjikian,Thibaud Mathis,FransescMarch de Ribot,Thanos Papakostas,Viraj Vasavada,Vaishali Vasavada,Samaresh Srivastava,Deepak Bhojwani,Pooja Ghia,Anand Sudhalkar
Indian Journal of Ophthalmology.2021;69(2)236
[DOI]
14Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration
Shruti Chandra,Jay Sheth,Giridhar Anantharaman,Mahesh Gopalakrishnan
American Journal of Ophthalmology Case Reports.2018;9(2)41
[DOI]
15The use of thalidomide to treat children with tuberculosis meningitis: A review
Ronald van Toorn,Stefan-Dan Zaharie,James A. Seddon,Martijn van der Kuip,A. Marceline van Furth,Johan F. Schoeman,Regan S. Solomons
Tuberculosis.2021;130(2)102125
[DOI]

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal